(Total Views: 201)
Posted On: 01/09/2018 5:43:42 PM
Post# of 72447
Here’s why I think Dr. Menon decided on 250 & 350 mg/m2 for the K-OC trial.
250 mg/m2 - the near disappearance of the spleen lesion in the ovarian cancer patient was due to 215 mg/m2 of K at once per week for three cycles.
350 mg/m2 - the slight tumor reduction in the thymoma cancer patient was due to 350 mg/m2 of K at once per week.
250 mg/m2 is well within the expected efficacy range of 200-300 mg/m2 according to Dr. Menon. Bashers said don’t expect to see any tumor response. If IPIX doesn’t think K might have an effect in tumors, they wouldn’t include efficacy as secondary endpoint (wasted time and money).
250 mg/m2 - the near disappearance of the spleen lesion in the ovarian cancer patient was due to 215 mg/m2 of K at once per week for three cycles.
350 mg/m2 - the slight tumor reduction in the thymoma cancer patient was due to 350 mg/m2 of K at once per week.
250 mg/m2 is well within the expected efficacy range of 200-300 mg/m2 according to Dr. Menon. Bashers said don’t expect to see any tumor response. If IPIX doesn’t think K might have an effect in tumors, they wouldn’t include efficacy as secondary endpoint (wasted time and money).
(6)
(0)
